Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treat...
11988 El Camino Real
San Diego, CA 92130
Founded in 2000
Celladon Corporation - Special Call
Apr 27 15
To discuss negative results for CUPID2 trial of MYDICAR(R) in advanced heart failure
Celladon Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014
Mar 31 15
Celladon Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of USD 10,958,000 against USD 5,977,000 a year ago. Consolidated net loss was USD 11,341,000 against USD 6,179,000 a year ago.
For the year, the company reported loss from operations of USD 33,018,000 against USD 19,964,000 a year ago. Consolidated net loss was USD 33,853,000 against USD 20,091,000 a year ago.
Celladon Seeks Acquisitions
Mar 31 15
Celladon Corporation (NasdaqGM:CLDN) announced an offering of 7 million of its common stocks and said that we intend to use the net proceeds from the sale of our common stock for general corporate purposes which may include clinical trial and other research and development expenses, capital expenditures, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products and technologies that complement our business, although we have no present commitments or agreements to make any such acquisitions or investments.